Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: A post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials

Autor: Charles P. Andrews, Myron J. Levin, Tino F. Schwarz, Lily Yin Weckx, Lidia Oostvogels, Covadonga Caso, Anthony L. Cunningham, Won Suk Choi, Angelo Pellegrino, Maria Luisa Rodriguez de la Pinta, Joon Hyung Kim, Tiina Korhonen, Edward M. F. Leung, Peter Eizenberg, Jackson H. Downey, David S.C. Hui, Janet E. McElhaney, Azhar Toma, Lars Rombo, Shelly A. McNeil, Wayne Ghesquiere, Roman Chlibek, Ilkka Seppa, Juan Carlos Tinoco, Silvia Narejos Perez, Daisuke Watanabe, Abiel Mascarenas de Los Santos, David O. Willer, Romulo E Colindres, Jose-Fernando Barba-Gomez, Anitta Ahonen, Anne Schuind, Carles Brotons Cuixart, Ferdinandus de Looze, Tommaso Staniscia, Alexander L. Thompson, Yeo Wilfred, Shinn-Jang Hwang, Iris Gorfinkel, Javier Díez Domingo, Meral Esen, Carla A. Talarico, Eugene Athan, Airi Poder, Johan Berglund, Jan Smetana, Pierre Gervais, Valentine Wascotte, Robert W. Johnson, Thiago Junqueira Avelino-Silva, Hideyuki Ikematsu, Karlis Pauksens, Maria Giuseppina Desole, Toufik Zahaf, Rodrigo Ribeiro dos Santos, Joan Puig Barbera
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
Herpesvirus 3
Human
030231 tropical medicine
Ethnic group
Neuralgia
Postherpetic
urologic and male genital diseases
Placebo
Herpes Zoster
law.invention
03 medical and health sciences
0302 clinical medicine
Sex Factors
Randomized controlled trial
Adjuvants
Immunologic
law
Internal medicine
Post-hoc analysis
medicine
Ethnicity
Herpes Zoster Vaccine
Humans
030212 general & internal medicine
Vaccine Potency
Aged
Aged
80 and over
Vaccines
Synthetic
General Veterinary
General Immunology and Microbiology
Geography
Postherpetic neuralgia
business.industry
Public Health
Environmental and Occupational Health
Middle Aged
Vaccine efficacy
medicine.disease
Infectious Diseases
Data Interpretation
Statistical
Vaccines
Subunit
Geographic regions
Molecular Medicine
Zoster vaccine
Female
business
medicine.drug
Zdroj: Vaccine. 37(43)
ISSN: 1873-2518
Popis: Background Herpes zoster (HZ) risk appears to vary by sex and geographic ancestry/ethnicity. Methods In 2 randomized clinical trials, participants received 2 doses of adjuvanted recombinant zoster vaccine (RZV) or placebo intramuscularly, 2 months apart. In this post-hoc analysis, we investigate efficacy of RZV against HZ and postherpetic neuralgia (PHN) by sex, geographic region, and geographic ancestry/ethnicity in ≥50-year-olds (ZOE-50: NCT01165177) and ≥70-year-olds (pooled data from ZOE-50 and ZOE-70: NCT01165229). Results Vaccine efficacy against HZ or PHN was similar in women and men. Across geographic regions, efficacy against HZ ranged between 95.7 and 97.2% in ≥50-year-olds, and between 87.3% and 95.1% in ≥70-year-olds; efficacy against PHN ranged between 86.8 and 100% in ≥70-year-olds. Across ancestral/ethnic groups, efficacy ranged between 88.1 and 100% against HZ and between 65.9 and 100% against PHN in ≥70-year-olds. Conclusions While the ZOE-50/70 studies were not powered or pre-designed for these post-hoc analyses, RZV appears efficacious against HZ and PHN irrespective of sex, region, or geographic ancestry/ethnicity.
Databáze: OpenAIRE
Externí odkaz: